Project Grant HT94252410032
Award Date 2/1/24
Completion Date 1/31/26
Dollars Obligated $310K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Kansas City, KS 66160, USA
Similar Awards
- This $309,528 Project Grant was awarded by the Defense Health Agency on February 1, 2024 under the Military Medical Research and Development program (CFDA 12.420) to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI). The grant supports a project titled "Evaluating the Role of Somatic Mutations in Autosomal Dominant Polycystic Kidney Disease Using Single-Cell Genomics", which aims to advance scientific understanding and treatment of this condition through...
- This federal Project Grant award of $1,383,874.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by the University of Maryland, Baltimore to decipher the intramolecular regulatory mechanism of polycystin 1, which is implicated in polycystic kidney disease. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing the scientific understanding of this...
- This $1,395,000 Project Grant award from the Department of Defense's Defense Health Agency was made to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) on April 1, 2024. The grant is funded under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research related to military medicine, with a focus on areas such as cancer and neurological disorders. The purpose of this 3-year grant is to develop a short peptide-based...
- The University of Kansas Medical Center Research Institute, Inc. (KUMCRI) was awarded a $930,000 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on March 1, 2024, supports research to investigate the progression of ductal carcinoma in situ (DCIS) to invasive basal-like breast cancer, with a focus on the role of N-RAS. The research aims to advance scientific knowledge and develop innovative therapies in the...
- This federal Project Grant award of $1,640,000.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research at The University of Texas Southwestern Medical Center (UT Southwestern) aimed at investigating the therapeutic parameters and mechanism of action of anti-miR-17 drugs in autosomal dominant polycystic kidney disease (ADPKD). The award period runs from April 1, 2025, to March 31, 2029. UT Southwestern, a...
- This $1,008,763.00 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the University of Pittsburgh on the role of the PROFILIN1 protein in chromophobe renal cell carcinoma, a type of kidney cancer. The research aims to investigate how PROFILIN1 impacts mitochondrial function and tumor development in this cancer type. The award period runs from September 1, 2025 through August 31, 2029. This grant is part of...
- The University of Kansas Medical Center Research Institute, Inc. (KUMCRI) was awarded a $766,886.00 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) on Sep 30, 2023. The 2-year grant supports research on the importance of NKG2D signaling-induced IL-24 secretion by tumor-specific CD8+ T cells. Through this biomedical research project, KUMCRI aims to investigate medical solutions that could transform health care for Service...
- This federal Project Grant award of $342,002.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The funding supports research at Western Michigan University Homer Stryker M.D. School of Medicine (WMED) to develop novel cellular tools for studying the regulation of the PKD1 gene in autosomal dominant polycystic kidney disease (ADPKD). The research aims to...
- This $728,513 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop a renal quantitative susceptibility mapping (QSM) technique for reliable detection and quantification of hemorrhagic cysts as a prognostic biomarker of kidney function decline in autosomal dominant polycystic kidney disease (ADPKD). The key objective is to leverage QSM...
- The University of Kansas Medical Center Research Institute, Inc. (KUMCRI) was awarded a $250,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award, effective July 1, 2025 and running through June 30, 2027, supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The research will focus on the biology of frailty in people with multiple...